Pentam and Bone lesion - a phase IV clinical study of FDA data

Summary:

Bone lesion is reported as a side effect among people who take Pentam (pentamidine isethionate), especially for people who are female, 50-59 old, also take Revlimid, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Bone lesion when taking Pentam. It is created by eHealthMe based on reports of 5,677 people who have side effects when taking Pentam from the FDA, and is updated regularly.

What is Pentam?

Pentam has active ingredients of pentamidine isethionate. eHealthMe is studying from 5,686 Pentam users. Check the latest studies of Pentam.

What is Bone lesion?

Bone lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries) is found to be associated with 856 drugs and 500 conditions by eHealthMe. Check the latest studies of Bone lesion.

On Jul, 18, 2026

5,677 people reported to have side effects when taking Pentam.
Among them, 16 people (0.28%) have Bone lesion.

Among these 16 people:

What is the gender of people who have Bone lesion when taking Pentam? *

female: 53.33 %
male: 46.67 %

What is the age of people who have Bone lesion when taking Pentam? *

What are other drugs people take besides Pentam? *

Zometa: 11 people, 68.75%
Aredia: 11 people, 68.75%
Velcade: 11 people, 68.75%
Thalidomide: 11 people, 68.75%
Cytoxan: 11 people, 68.75%
Revlimid: 11 people, 68.75%
Melphalan Hydrochloride: 10 people, 62.50%
Augmentin '125': 10 people, 62.50%
Decadron: 10 people, 62.50%
Xanax: 9 people, 56.25%

What are other side effects people have besides Bone lesion? *

Pain: 11 people, 68.75%
Suicidal Ideation: 11 people, 68.75%
Neuropathy Peripheral (surface nerve damage): 11 people, 68.75%
Anaemia (lack of blood): 11 people, 68.75%
Depression: 11 people, 68.75%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 11 people, 68.75%
Thrombocytopenia (decrease of platelets in blood): 11 people, 68.75%
Weight Decreased: 11 people, 68.75%
Joint Pain: 10 people, 62.50%
Hypoaesthesia (reduced sense of touch or sensation): 10 people, 62.50%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 13 people, 81.25%
Diabetes: 5 people, 31.25%
Precursor B-Lymphoblastic Lymphoma Refractory (precursor b-cell cancer- refractory): 3 people, 18.75%
Stress And Anxiety: 2 people, 12.50%
Osteoporosis (bones weak and more likely to break): 1 person, 6.25%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 6.25%
Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 6.25%
High Blood Pressure: 1 person, 6.25%
Bone Loss: 1 person, 6.25%
B Precursor Type Acute Leukaemia (lymphoid cancer): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Pentam and have Bone lesion?

- Check whether Bone lesion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pentam:

Pentam (5,686 reports)

Bone lesion treatments and more:

Bone lesion (6,686 reports)

Browse all side effects of Pentam:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bone lesion:

Bone lesion (857 drugs)

Browse all the conditions that are associated with Bone lesion:

Bone lesion (500 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pentamidine isethionate (the active ingredients of Pentam) and Pentam (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.